Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Guidelines on Red Cell Transfusion in Sickle Cell Disease. Part I: Principles and Laboratory Aspects
source: British Society for Haematology
year: 2016
authors: B A Davis, S Allard, A Qureshi, J B Porter, S Pancham, N Win, G Cho, K Ryan
summary/abstract:Blood transfusion in the management of sickle cell disease (SCD) can be lifesaving and reduces disability. However, it may cause morbidity, including alloimmunisation and iron overload (Ballas 2001, Darbari, et al 2006, Rosse, et al 1990, Vichinsky, et al 1990), and mortality (Royal and Seeler 1978, Serjeant 2003).
A paucity of randomised controlled clinical trials has resulted in wide variations in clinical practice. However, recent randomised studies have addressed some of the outstanding issues around indications to prevent some chronic complications (DeBaun, et al 2014) and to prevent perioperative acute complications, such as acute chest syndrome (Howard, et al 2013). We have reviewed the evidence and developed two linked guidelines on transfusion in SCD; Part I relates to general principles and laboratory aspects, whereas Part II addresses indications for transfusion in sickle cell disease. Here the term sickle cell disease refers to all genotypes of the disease and sickle cell anaemia to the homozygous state (SS).
read more
+myBinderRelated Content
-
Pharmacogenetics for Safe Codeine Use in Sickle Cell DiseaseAfter postoperative deaths in children w...
-
Sickle cell disease cure in sights of UAB Stem Cell InstituteTim Townes has a dream. He has a dream t...
-
100 Years But Only One Drug: Sickle Cell Patients Wait For HelpLast week, 100,000 Americans with sickle...
-
Pediatric Residents’ Perceived Barriers to Opioid Use in Sickle Cell Disease Pain ManagementObjective: Current guidelines recommend...
-
Acetylon Presents Preclinical Data Demonstrating the Utility of Selective HDAC1,2 Inhibition by ACY-957 to Induce Ga...Acetylon Pharmaceuticals, Inc., the lead...
-
Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell ...ArQule, Inc. (Nasdaq: ARQL) today announ...
-
Study Confirms Safe Use of Opioids for Pain Control in Sickle Cell DiseaseThe most common cause of hospital admiss...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.